Royalty Pharma Lifts Receipts Outlook to $3.5B

The biopharma royalty firm's guidance rises even as a pelacarsen impairment cuts quarterly net income.

Updated on Nov. 5, 2026 in Biotech

Royalty Pharma Lifts Receipts Outlook to $3.5B

Royalty Pharma raised its 2026 Portfolio Receipts outlook to $3.5 billion to $3.55 billion in its third-quarter 2025 report. The company reported net income attributable to Royalty Pharma of $144.7 million, down from $284.2 million a year earlier; the company is a financial business, not a drug product, so its guidance is not a shipped therapy.

Why it matters

Royalty Pharma earns income by acquiring royalty interests in approved and late-stage drugs and co-funding development, so its receipts track how those drugs sell. The quarter's growth was attributed mainly to Tremfya, Voranigo, Evrysdi and Imdelltra, while a $150.4 million impairment tied to pelacarsen reflected a failed Phase 3 readout from Novartis.

Third-quarter total income and other revenues rose to $690.1 million from $609.3 million, and the company generated $686 million in net cash from operating activities. Diluted earnings per Class A share fell to 32 cents from 66 cents, and total debt principal stood at $8.8 billion against $514 million in cash as of Sept. 30.

The players

Royalty Pharma

A biopharmaceutical royalty company that acquires royalty interests and co-funds drug development, with a portfolio spanning marketed and late-stage medicines.

Novartis

A Swiss pharmaceutical company with a large immunology, neuroscience and cardiovascular portfolio, which sponsored the Phase 3 Lp(a)HORIZON trial of pelacarsen.

The details

Royalty Pharma buys the right to a share of future sales from biopharmaceutical products, a financing structure called a royalty interest, and it also funds drug development through co-funding agreements. Its receipts therefore rise when the underlying drugs sell more, and a noncash impairment is recorded when an asset's expected future payments fall. In this quarter, the $150.4 million charge followed Novartis's report that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint.

Sept. 30, 2025: Comparison quarter for Portfolio Receipts and net income.
Nov. 4, 2026: Third-quarter results released; guidance excludes later transactions.
Sept. 30, 2026: Third quarter ended for reported receipts and cash position.
2026: Full-year Portfolio Receipts outlook raised to $3.5 billion to $3.55 billion.

The Tech Race

Royalty Pharma's model competes for capital against other drug-royalty and synthetic-royalty financiers that fund late-stage biotech assets. Its result shows how a single failed Phase 3 readout, such as pelacarsen, can move an otherwise growing royalty portfolio's reported earnings.

The results affect investors and drug-royalty partners more than patients directly, since Royalty Pharma's income depends on sales of drugs it has financed. The raised outlook excludes transactions announced after Nov. 4, so the company's future deal activity remains unannounced.

The takeaway

Royalty Pharma's receipts growth depends on how its royalty drugs keep selling, so the next signals to track are its full-year 2026 results and any new transactions announced after Nov. 4. Watch whether further impairments follow the pelacarsen write-down in future quarters.